Recent clinical trials have demonstrated that the SchistoShield® vaccine candidate for schistosomiasis elicits strong immune memory responses. Schistosomiasis, caused by helminth parasites of the Schistosoma genus, leads to approximately 290,000 deaths annually and affects an estimated 250 million people worldwide, particularly in tropical and subtropical regions.
The vaccine, which has successfully completed Phase I and Phase Ib trials in the U.S. and Africa, respectively, has shown promise in inducing both adaptive immune effector and memory responses. Research published in npj Vaccines highlights the robust T-cell responses generated by the vaccine, a crucial indicator of its potential efficacy against schistosome infections.
Dr. Afzal Siddiqui, a key figure in the vaccine’s development, emphasizes the significance of these findings, noting that while initial results are promising, further large-scale trials involving thousands of participants are essential for confirming the vaccine’s effectiveness. Given the limited treatment options currently available for schistosomiasis, the development of SchistoShield represents a critical advancement in addressing this neglected tropical disease and expanding access to care for affected populations.
Use the database as your supply chain compass →
